Investment
Features
FeesSafety
Academy
More
Pluang+

AWS funds Myseum.AI's privacy-first AI album tool for Picture Party social platform

Market News
22 Jul 2026
GlobeNewsWire
View Source
Bullish
AWS funds Myseum.AI's privacy-first AI album tool for Picture Party social platform

Myseum.AI announced that Amazon Web Services (AWS) is funding part of the development of its privacy-first AI album creation and media management tool for the Picture Party social media platform. The tool uses localized AI to help users manage personal media like photos and videos while ensuring privacy through encryption and no data sharing with other platforms. Partnering with AWS Premier Partner Caylent, Myseum.AI aims to enhance user experience without compromising privacy. The Picture Party app is available on iOS and Google Play, with a desktop version expected later this year.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
43 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
ACRES Commercial Realty approves $5M more for share buyback program

ACRES Commercial Realty approves $5M more for share buyback program

ACRES Commercial Realty Corp. announced its board approved an additional $5 million for its existing share repurchase program. The company plans to buy back shares through various methods depending on market conditions but has not set a specific time...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App